SWE ORPHAN BIOVITRU (B6E MU) stock market data APIs
€29.7482
0.04(0.1%)
as of December 19, 2025
Try our APIs with
free plan!
SWE ORPHAN BIOVITRU Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for B6E.MU.
Prev. Close
29.7482
Open
29.983
High
30.0123
Low
29.5856
52 wk Range
22.96-31.84
Market Cap
5 414 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SWE ORPHAN BIOVITRU data using free add-ons & libraries
Get SWE ORPHAN BIOVITRU Fundamental Data
SWE ORPHAN BIOVITRU Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SWE ORPHAN BIOVITRU News
New
How New Catalysts Are Shifting the Narrative for Swedish Orphan Biovitrum Stock
Swedish Orphan Biovitrum's updated narrative now centers on a slightly higher fair value estimate of SEK 367.09, up from SEK 360.36, paired with a marginally higher discount rate of 5.34% that reflect...
Save the Date: Sobi to host a Capital Markets Day on 18 February 2026
STOCKHOLM, Dec. 18, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person...
Assessing Swedish Orphan Biovitrum (OM:SOBI)’s Valuation After Its Recent Share Price Rebound
Swedish Orphan Biovitrum (OM:SOBI) has been quietly rewarding patient shareholders, and the recent bounce in the share price is a good moment to step back and reassess what the market is really pricin...
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
- Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout - Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory SAN DIEGO, De...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
